

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8209618

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
CITIBANK, N.A.	10/06/2023

RECEIVING PARTY DATA

Name:	HORIZON THERAPEUTICS USA, INC.
Street Address:	1 HORIZON WAY
City:	DEERFIELD
State/Country:	ILLINOIS
Postal Code:	60015

PROPERTY NUMBERS Total: 44

Property Type	Number
Application Number:	60219318
PCT Number:	US1999017514
Patent Number:	6576235
Patent Number:	7723089
Patent Number:	7927589
Patent Number:	8067553
Application Number:	12769572
Patent Number:	8618267
Application Number:	13306336
Application Number:	14806494
Patent Number:	6783965
Application Number:	10928370
Patent Number:	7927852
Patent Number:	8921064
Application Number:	14462368
PCT Number:	US0140069
Application Number:	60095489
PCT Number:	US1999017678
Patent Number:	7056713
Application Number:	11357028

PATENT

Property Type	Number
PCT Number:	US2006013660
Application Number:	60670573
Patent Number:	9017980
Application Number:	14671246
Patent Number:	8541205
Patent Number:	8188224
PCT Number:	US2006013502
Application Number:	60670541
Patent Number:	8034594
Patent Number:	8178334
Patent Number:	8293228
Patent Number:	8465735
Patent Number:	7964381
Patent Number:	7811800
PCT Number:	US2006013751
Application Number:	60670520
Application Number:	11918292
PCT Number:	US2010040082
Application Number:	61269669
Application Number:	61298718
Application Number:	13379704
Patent Number:	8148123
Application Number:	11899688
Patent Number:	8545879

CORRESPONDENCE DATA

Fax Number: (212)291-9868

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (212) 558-4229

Email: demarcor@sullcrom.com, nguyenb@sullcrom.com

Correspondent Name: RAFFAELE A. DEMARCO

Address Line 1: 125 BROAD STREET

Address Line 2: SULLIVAN & CROMWELL LLP

Address Line 4: NEW YORK, NEW YORK 10004

ATTORNEY DOCKET NUMBER:	019095.00083 (RAD)
NAME OF SUBMITTER:	RAFFAELE A. DEMARCO
SIGNATURE:	/Raffaele A. DeMarco/
DATE SIGNED:	10/06/2023

Total Attachments: 24

source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page1.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page2.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page3.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page4.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page5.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page6.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page7.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page8.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page9.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page10.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page11.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page12.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page13.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page14.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page15.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page16.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page17.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page18.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page19.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page20.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page21.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page22.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page23.tif
source=Horizon- Patent Release (March 2016 PSA) (Agreed Form)#page24.tif

RELEASE OF SECURITY INTEREST IN PATENTS

This RELEASE OF SECURITY INTEREST IN PATENTS (this “Release”), dated as of October 6, 2023 (the “Effective Date”), is made by Citibank, N.A., in its capacity as Administrative Agent and Collateral Agent (the “Agent”), in favor of the grantor party identified on the signature page hereto (the “Grantor”).

WHEREAS, pursuant to that certain U.S. Pledge and Security Agreement, dated as of May 7, 2015, by and among the Agent, the Grantor and certain other parties thereto (as amended, amended and restated, or otherwise modified from time to time, the “Security Agreement”), the Grantor granted to the Agent, in its capacity as Administrative Agent and Collateral Agent, a security interest in and to certain collateral;

WHEREAS, pursuant to the Security Agreement, the Grantor executed and delivered a Patent Security Agreement, dated as of March 11, 2016 (the “March 2016 Patent Security Agreement”), for recordal with the United States Patent and Trademark Office;

WHEREAS, the March 2016 Patent Security Agreement was recorded with the United States Patent and Trademark Office on September 16, 2016 at Reel/Frame 040059/0007.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

1. Defined Terms. All capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Security Agreement or the December 2019 Patent Security Agreement, as applicable.
2. Release. The Agent, without representation or warranty of any kind, hereby irrevocably releases, discharges, terminates and cancels all of its security interest in all of the Grantor’s right, title and interest, wherever located, in and to: (i) any and all patents and patent applications that were granted in connection with the March 2016 Patent Security Agreement, including those listed on Schedule 1 hereto; (ii) all inventions and improvements described and claimed therein; (iii) all reissues, divisions, continuations, renewals, extensions, and continuations-in-part thereof; (iv) all income, royalties, damages, claims, and payments now or hereafter due or payable under and with respect thereto, including, without limitation, damages and payments for past and future infringements thereof; (v) all rights to sue for past, present, and future infringements thereof; and (vi) all rights corresponding to any of the foregoing throughout the world.
3. Termination. The Agent, without representation or warranty of any kind, terminates and cancels the March 2016 Patent Security Agreement.
4. Recordation. The Agent hereby authorizes and requests that the Commissioner for Patents of the United States Patent and Trademark Office record this Release.
5. Further Assurances. The Agent agrees to take all further actions, and provide to the Grantor and its successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by the Grantor, at the Grantor’s sole cost and expense, to more fully and effectively effectuate the purposes of this Release.

6. Governing Law. This Release shall be governed exclusively under the laws of the State of New York, without regard to conflicts of law or choice of law principles.

[Signature Page Follows]

IN WITNESS WHEREOF, the Agent has caused this Release to be executed by its duly authorized representative as of the Effective Date:

**CITIBANK, N.A., acting in its capacity as
Administrative Agent and Collateral Agent**

By: Kevin B. Ciok

Name: Kevin Ciok

Title: Vice President

GRANTOR:

**HORIZON THERAPEUTICS USA,
INC.**

SCHEDULE 1

PATENTS

	Owner	Territory	Patent Title	Serial No. Filing Date	Patent No. Issue Date
1.	Crealta Pharmaceuticals LLC and Duke University	US	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	60219318 8/6/1998	
2.	Mountain View Pharmaceuticals and Duke University	WO	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	PCT/US99/1751 4 8/2/1999	
3.	Crealta Pharmaceuticals LLC and Duke University	US	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09370084 8/6/1999	6576235 6/10/2003
4.	Crealta Pharmaceuticals LLC and Duke University	US	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09839946 4/19/2001	7723089 5/25/2010
5.	Crealta Pharmaceuticals LLC and Duke University	US	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	11833590 8/3/2007	7927589 4/19/2011
6.	Crealta Pharmaceuticals LLC and Duke University	US	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	12769570 4/28/2010	8067553 11/29/2011
7.	Crealta Pharmaceuticals LLC and Duke University	US	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	12769572 4/28/2010	
8.	Crealta Pharmaceuticals LLC and Duke University	US	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	13083152 4/8/2011	8618267 12/31/2013
9.	Crealta Pharmaceuticals LLC and Duke University	US	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	13306336 11/29/2011	
10.	Crealta Pharmaceuticals LLC and Duke University	US	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	14806494 7/22/2015	
11.	Mountain View Pharmaceuticals and Duke University	EP	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
12.	Mountain View Pharmaceuticals and Duke University	HK	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	01108240.0 8/2/1999	HK1037330 12/2/2005
13.	Mountain View Pharmaceuticals and Duke University	DE	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	69925917-7 6/22/2005
14.	Mountain View Pharmaceuticals and Duke University	DK	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
15.	Mountain View Pharmaceuticals and Duke University	ES	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
16.	Mountain View Pharmaceuticals and Duke University	FI	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
17.	Mountain View Pharmaceuticals and Duke University	FR	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
18.	Mountain View Pharmaceuticals and Duke University	GB	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
19.	Mountain View Pharmaceuticals and Duke University	GR	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
20.	Mountain View Pharmaceuticals and Duke University	IE	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
21.	Mountain View Pharmaceuticals and Duke University	IT	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
22.	Mountain View Pharmaceuticals and Duke University	LI	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005

23.	Mountain View Pharmaceuticals and Duke University	LU	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
24.	Mountain View Pharmaceuticals and Duke University	MC	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
25.	Mountain View Pharmaceuticals and Duke University	NL	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
26.	Mountain View Pharmaceuticals and Duke University	PT	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
27.	Mountain View Pharmaceuticals and Duke University	SE	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
28.	Mountain View Pharmaceuticals and Duke University	AT	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
29.	Mountain View Pharmaceuticals and Duke University	BE	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
30.	Mountain View Pharmaceuticals and Duke University	CH	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
31.	Mountain View Pharmaceuticals and Duke University	EP	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
32.	Mountain View Pharmaceuticals and Duke University	AT	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	AT498409T 2/16/2011
33.	Mountain View Pharmaceuticals and Duke University	BE	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
34.	Mountain View Pharmaceuticals and Duke University	CH	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
35.	Mountain View Pharmaceuticals and Duke University	LI	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
36.	Mountain View Pharmaceuticals and Duke University	CY	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	CY1112287 2/16/2011
37.	Mountain View Pharmaceuticals and Duke University	DE	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	DE69943205 2/16/2011
38.	Mountain View Pharmaceuticals and Duke University	DK	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
39.	Mountain View Pharmaceuticals and Duke University	ES	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	ES2245114 2/16/2011
40.	Mountain View Pharmaceuticals and Duke University	FI	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
41.	Mountain View Pharmaceuticals and Duke University	FR	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
42.	Mountain View Pharmaceuticals and Duke University	GB	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
43.	Mountain View Pharmaceuticals and Duke University	GR	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
44.	Mountain View Pharmaceuticals and Duke University	IE	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
45.	Mountain View Pharmaceuticals and Duke University	IT	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
46.	Mountain View Pharmaceuticals and Duke University	LU	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
47.	Mountain View Pharmaceuticals and Duke University	MC	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
48.	Mountain View Pharmaceuticals and Duke University	NL	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011

49.	Mountain View Pharmaceuticals and Duke University	PT	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
50.	Mountain View Pharmaceuticals and Duke University	SE	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	05011069.1 8/2/1999	1588716 2/16/2011
51.	Mountain View Pharmaceuticals and Duke University	EP	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 5/23/2009	2158923 2/27/2013
52.	Mountain View Pharmaceuticals and Duke University	HK	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	10108340.8 9/2/2010	1141738B 11/22/2013
53.	Mountain View Pharmaceuticals and Duke University	AT	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	AT598145T 2/27/2013
54.	Mountain View Pharmaceuticals and Duke University	BE	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
55.	Mountain View Pharmaceuticals and Duke University	CY	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	CY1114005 2/27/2013
56.	Mountain View Pharmaceuticals and Duke University	DK	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
57.	Mountain View Pharmaceuticals and Duke University	FI	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
58.	Mountain View Pharmaceuticals and Duke University	FR	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
59.	Mountain View Pharmaceuticals and Duke University	DE	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	DE6944647.3 2/27/2013
60.	Mountain View Pharmaceuticals and Duke University	GR	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
61.	Mountain View Pharmaceuticals and Duke University	IE	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
62.	Mountain View Pharmaceuticals and Duke University	IT	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
63.	Mountain View Pharmaceuticals and Duke University	LU	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
64.	Mountain View Pharmaceuticals and Duke University	MC	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
65.	Mountain View Pharmaceuticals and Duke University	NL	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
66.	Mountain View Pharmaceuticals and Duke University	PT	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
67.	Mountain View Pharmaceuticals and Duke University	ES	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
68.	Mountain View Pharmaceuticals and Duke University	SE	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
69.	Mountain View Pharmaceuticals and Duke University	CH	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
70.	Mountain View Pharmaceuticals and Duke University	LI	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
71.	Mountain View Pharmaceuticals and Duke University	GB	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	09175303.8 8/2/1999	2158923 2/27/2013
72.	Mountain View Pharmaceuticals and Duke University	EP	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	10180672.7 8/2/1999	
73.	Mountain View Pharmaceuticals and Duke University	HK	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	11109398.6 9/6/2011	
74.	Mountain View Pharmaceuticals and Duke University	AU	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	52515/99 8/2/1999	
75.	Mountain View Pharmaceuticals and Duke University	BR	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	PI9912974-4 8/2/1999	

76.	Mountain View Pharmaceuticals and Duke University	BR	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	PI9912974-9 82/1999	
77.	Mountain View Pharmaceuticals and Duke University	CA	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	2338665 8/2/1999	2338665 1/18/2011
78.	Mountain View Pharmaceuticals and Duke University	CA	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	2728907 8/2/1999	2728907 1/18/2011
79.	Mountain View Pharmaceuticals and Duke University	CN	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99811845.1 8/2/1999	ZL99811845.1 7/19/2006
80.	Mountain View Pharmaceuticals and Duke University	CN	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	200610084131.8 8/2/1999	ZL0610084131.8 9/5/2012
81.	Mountain View Pharmaceuticals and Duke University	HK	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	07107259.4 8/2/1999	1103303B 6/7/2013
82.	Mountain View Pharmaceuticals and Duke University	CN	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	201010565549.7 8/2/1999	
83.	Mountain View Pharmaceuticals and Duke University	CY	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	99937745.0 8/2/1999	1100542 6/22/2005
84.	Mountain View Pharmaceuticals and Duke University	CZ	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	PV2001317 8/2/1999	CZ303751B6 3/13/2013
85.	Mountain View Pharmaceuticals and Duke University	CZ	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	2012-354 8/2/1999	
86.	Mountain View Pharmaceuticals and Duke University	HU	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	P0103003 8/2/1999	HU226294B1 6/30/2008
87.	Mountain View Pharmaceuticals and Duke University	IL	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	141220 8/2/1999	141220 12/21/2007
88.	Mountain View Pharmaceuticals and Duke University	IL	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	183948 8/2/1999	183948 3/1/2011
89.	Mountain View Pharmaceuticals and Duke University	IN	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	IN/PCT/01/0013 3	233652 4/1/2009
90.	Mountain View Pharmaceuticals and Duke University	IN	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	1899/KOL NP/06 8/2/1999	
91.	Mountain View Pharmaceuticals and Duke University	IN	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	532/KOL NP/2009 2/9/2009	
92.	Mountain View Pharmaceuticals and Duke University	JP	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	2000-563311 8/2/1999	5183839 1/25/2013
93.	Mountain View Pharmaceuticals and Duke University	JP	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	2009-173148 8/2/1999	5290901 6/14/2013
94.	Mountain View Pharmaceuticals and Duke University	JP	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	2012-248770 8/2/1999	5291235 6/14/2013
95.	Mountain View Pharmaceuticals and Duke University	KR	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	7001569/2001 8/2/1999	0488848 5/2/2005
96.	Mountain View Pharmaceuticals and Duke University	KR	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	7014428/2004 8/2/1999	10-0614212 8/21/2006
97.	Mountain View Pharmaceuticals and Duke University	MX	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	PA/a/2001/0012 72	232518 12/1/2005
98.	Mountain View Pharmaceuticals and Duke University	NZ	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	509595 8/2/1999	509595 6/8/2004
99.	Mountain View Pharmaceuticals and Duke University	PL	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	P-346224 8/2/1999	203492 1/18/2010
100.	Mountain View Pharmaceuticals and Duke University	PL	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	P-380583 8/2/1999	202799 10/28/2009

101.	Mountain View Pharmaceuticals and Duke University	PL	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	P-383331 8/2/1999	
102.	Mountain View Pharmaceuticals and Duke University	RU	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	2001/103144 8/2/1999	2246318 2/20/2005
103.	Mountain View Pharmaceuticals and Duke University	RU	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	2004/104953/15 8/2/1999	2278680 6/27/2006
104.	Mountain View Pharmaceuticals and Duke University	RU	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	2006/107111 8/2/1999	2349341 3/20/2009
105.	Mountain View Pharmaceuticals and Duke University	RU	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	2008/132767 7/11/2008	2443426 2/27/2012
106.	Mountain View Pharmaceuticals and Duke University	SG	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	2001/00559-4 8/2/1999	78843 3/31/2003
107.	Mountain View Pharmaceuticals and Duke University	TW	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	88113406 8/5/1999	194583 5/10/2004
108.	Mountain View Pharmaceuticals and Duke University	ZA	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	2001/01814 8/2/1999	2001/01814 7/31/2002
109.	Mountain View Pharmaceuticals and Duke University	HU	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	P0800112 8/2/1999	228916 5/28/2013

110.	Crealta Pharmaceuticals LLC and Duke University	US	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	09501730 2/10/2000	6783965 8/31/2004
111.	Crealta Pharmaceuticals LLC and Duke University	US	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10928370 8/30/2004	
112.	Crealta Pharmaceuticals LLC and Duke University	US	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	11882750 8/30/2007	7927852 4/19/2011
113.	Crealta Pharmaceuticals LLC and Duke University	US	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	13085793 4/13/2011	8921064 12/30/2014
114.	Crealta Pharmaceuticals LLC and Duke University	US	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	14462368 8/18/2014	
115.	Mountain View Pharmaceuticals and Duke University	WO	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	PCT/US01/4006 9 2/7/2001	
116.	Mountain View Pharmaceuticals and Duke University	AU	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2001249975 2/7/2001	2001249975 9/21/2006
117.	Mountain View Pharmaceuticals and Duke University	AU	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2006203252 2/7/2001	2006203252 1/21/2010
118.	Mountain View Pharmaceuticals and Duke University	AU	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2009212900 2/7/2001	2009212900 12/8/2011
119.	Mountain View Pharmaceuticals and Duke University	BR	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	PI 0108386-4 2/7/2001	
120.	Mountain View Pharmaceuticals and Duke University	CA	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2398679 2/7/2001	23986779 2/2/2015
121.	Mountain View Pharmaceuticals and Duke University	CN	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01807750.1 2/7/2001	ZL01807750.1 5/27/2009

122.	Mountain View Pharmaceuticals and Duke University	HK	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	03109064.9 2/7/2001	1056742 11/27/2009
123.	Mountain View Pharmaceuticals and Duke University	CN	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	200910127853.0 4/2/2009	1271411 9/11/2013
124.	Mountain View Pharmaceuticals and Duke University	HK	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10111402.7 12/8/2010	1144701 6/6/2014
125.	Mountain View Pharmaceuticals and Duke University	CZ	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2002-2982 2/7/2001	304864 11/5/2014
126.	Mountain View Pharmaceuticals and Duke University	EP	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
127.	Mountain View Pharmaceuticals and Duke University	AT	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
128.	Mountain View Pharmaceuticals and Duke University	BE	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
129.	Mountain View Pharmaceuticals and Duke University	CH	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
130.	Mountain View Pharmaceuticals and Duke University	CY	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
131.	Mountain View Pharmaceuticals and Duke University	DE	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
132.	Mountain View Pharmaceuticals and Duke University	DK	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
133.	Mountain View Pharmaceuticals and Duke University	ES	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
134.	Mountain View Pharmaceuticals and Duke University	FI	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
135.	Mountain View Pharmaceuticals and Duke University	FR	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
136.	Mountain View Pharmaceuticals and Duke University	GB	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
137.	Mountain View Pharmaceuticals and Duke University	GR	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
138.	Mountain View Pharmaceuticals and Duke University	IE	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
139.	Mountain View Pharmaceuticals and Duke University	IT	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
140.	Mountain View Pharmaceuticals and Duke University	LI	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010

141.	Mountain View Pharmaceuticals and Duke University	LU	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
142.	Mountain View Pharmaceuticals and Duke University	MC	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
143.	Mountain View Pharmaceuticals and Duke University	NL	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
144.	Mountain View Pharmaceuticals and Duke University	PT	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
145.	Mountain View Pharmaceuticals and Duke University	SE	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
146.	Mountain View Pharmaceuticals and Duke University	TR	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	01923265.1 2/7/2001	1254237 4/7/2010
147.	Mountain View Pharmaceuticals and Duke University	HK	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10110105.9 10/27/2010	
148.	Mountain View Pharmaceuticals and Duke University	EP	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
149.	Mountain View Pharmaceuticals and Duke University	AT	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
150.	Mountain View Pharmaceuticals and Duke University	BE	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
151.	Mountain View Pharmaceuticals and Duke University	CY	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
152.	Mountain View Pharmaceuticals and Duke University	DK	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
153.	Mountain View Pharmaceuticals and Duke University	FI	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
154.	Mountain View Pharmaceuticals and Duke University	FR	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
155.	Mountain View Pharmaceuticals and Duke University	DE	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
156.	Mountain View Pharmaceuticals and Duke University	GR	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
157.	Mountain View Pharmaceuticals and Duke University	IE	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
158.	Mountain View Pharmaceuticals and Duke University	IT	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
159.	Mountain View Pharmaceuticals and Duke University	LI	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014

160.	Mountain View Pharmaceuticals and Duke University	LU	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
161.	Mountain View Pharmaceuticals and Duke University	MC	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
162.	Mountain View Pharmaceuticals and Duke University	NL	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
163.	Mountain View Pharmaceuticals and Duke University	PT	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
164.	Mountain View Pharmaceuticals and Duke University	ES	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
165.	Mountain View Pharmaceuticals and Duke University	SE	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
166.	Mountain View Pharmaceuticals and Duke University	CH	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
167.	Mountain View Pharmaceuticals and Duke University	TR	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
168.	Mountain View Pharmaceuticals and Duke University	GB	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10180428.4 2/7/2001	2305819 11/12/2014
169.	Mountain View Pharmaceuticals and Duke University	HK	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	11109405.7 9/6/2011	
170.	Mountain View Pharmaceuticals and Duke University	HU	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	0204544 2/7/2001	227127 10/12/2010
171.	Mountain View Pharmaceuticals and Duke University	IL	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	151065 2/7/2001	151065 3/30/2009
172.	Mountain View Pharmaceuticals and Duke University	IL	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	193365 2/7/2001	193365 12/1/2011
173.	Mountain View Pharmaceuticals and Duke University	IN	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	IN/PCT/2002/00 983 2/7/2001	226519 12/17/2008
174.	Mountain View Pharmaceuticals and Duke University	JP	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2001-558218 2/7/2001	5165826 12/28/2012
175.	Mountain View Pharmaceuticals and Duke University	JP	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2011-188861 2/7/2001	5341945 8/16/2013
176.	Mountain View Pharmaceuticals and Duke University	KR	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	7010189/2002 2/7/2001	10-0884724 1/29/2009
177.	Mountain View Pharmaceuticals and Duke University	KR	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	7018682/2007 2/7/2001	
178.	Mountain View Pharmaceuticals and Duke University	KR	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	10-2008- 7024272 10/2/2008	10-1054247 7/29/2011

179.	Mountain View Pharmaceuticals and Duke University	MX	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	PA/a/2002/0075 45 2/7/2001	233195 12/20/2005
180.	Mountain View Pharmaceuticals and Duke University	MX	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	PA/a/2005/0138 92 2/7/2001	279587 9/29/2010
181.	Mountain View Pharmaceuticals and Duke University	NZ	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	520434 2/7/2001	520434 9/9/2004
182.	Mountain View Pharmaceuticals and Duke University	PL	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	P-358539 2/7/2001	208064 11/5/2010
183.	Mountain View Pharmaceuticals and Duke University	RU	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2002 120486/13 2/7/2001	2281954 8/20/2006
184.	Mountain View Pharmaceuticals and Duke University	RU	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2006/107110 2/7/2001	2352354 4/20/2009
185.	Mountain View Pharmaceuticals and Duke University	RU	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2009/104003 2/7/2001	12/25/2014
186.	Mountain View Pharmaceuticals and Duke University	SG	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2002/04601-9 2/7/2001	90846 11/30/2004
187.	Mountain View Pharmaceuticals and Duke University	TW	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	90102540 2/6/2001	I 322184 3/21/2010
188.	Mountain View Pharmaceuticals and Duke University	TW	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	97145974 2/6/2001	
189.	Mountain View Pharmaceuticals and Duke University	ZA	AGGREGATE-FREE URATE IXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2002/7206 2/7/2001	2002/7206 7/30/2003

190.	Duke University of Durham, NC	US	URATE OXIDASE	60/095489 8/6/1998	
191.	Duke University of Durham, NC	WO	URATE OXIDASE	PCT/US1999/01 7678 8/5/1999	
192.	Duke University of Durham, NC	US	URATE OXIDASE	09762097 8/5/1999	7056713 6/6/2006
193.	Duke University of Durham, NC	US	URATE OXIDASE	11357028 2/21/2006	
194.	Duke University of Durham, NC	AU	URATE OXIDASE	53365/99 8/5/1999	766421 1/29/2004
195.	Duke University of Durham, NC	BR	URATE OXIDASE	PI9913360-1 8/5/1999	PI9913360-1 9/24/2013
196.	Duke University of Durham, NC	CA	URATE OXIDASE	2337967 8/5/1999	2337967 11/1/2011
197.	Duke University of Durham, NC	CN	URATE OXIDASE	99811738.2 8/5/1999	
198.	Duke University of Durham, NC	CN	URATE OXIDASE	200810086651.1 8/5/1999	ZL20081008665 1.1 9/11/2013

199.	Duke University of Durham, NC	HK	URATE OXIDASE	01108032.2 8/5/1999	HK1037214 5/6/2011
200.	Duke University of Durham, NC	HK	URATE OXIDASE	09103159.2 8/5/1999	
201.	Duke University of Durham, NC	EP	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
202.	Duke University of Durham, NC	DE	URATE OXIDASE	99938996.8 8/5/1999	69942834.3 10/6/2010
203.	Duke University of Durham, NC	DK	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
204.	Duke University of Durham, NC	ES	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
205.	Duke University of Durham, NC	FI	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
206.	Duke University of Durham, NC	FR	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
207.	Duke University of Durham, NC	GB	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
208.	Duke University of Durham, NC	GR	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
209.	Duke University of Durham, NC	IE	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
210.	Duke University of Durham, NC	IT	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
211.	Duke University of Durham, NC	LU	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
212.	Duke University of Durham, NC	MC	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
213.	Duke University of Durham, NC	NL	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
214.	Duke University of Durham, NC	PT	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
215.	Duke University of Durham, NC	SE	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
216.	Duke University of Durham, NC	AT	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
217.	Duke University of Durham, NC	BE	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
218.	Duke University of Durham, NC	CH/LI	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
219.	Duke University of Durham, NC	CY	URATE OXIDASE	99938996.8 8/5/1999	1100880 10/6/2010
220.	Duke University of Durham, NC	EP	URATE OXIDASE	10007912.8 8/5/1999	
221.	Duke University of Durham, NC	HK	URATE OXIDASE	11107610.2 8/5/1999	

222.	Duke University of Durham, NC	HU	URATE OXIDASE	P0103205 8/5/1999	
223.	Duke University of Durham, NC	IL	URATE OXIDASE	141221 8/5/1999	141221 9/17/2010
224.	Duke University of Durham, NC	IL	URATE OXIDASE	197339 8/5/1999	
225.	Duke University of Durham, NC	IN	URATE OXIDASE	IN/PCT/2001/01 65 8/5/1999	228221 1/28/2009
226.	Duke University of Durham, NC	JP	URATE OXIDASE	2000-563819 8/5/1999	
227.	Duke University of Durham, NC	JP	URATE OXIDASE	2010-021520 8/5/1999	
228.	Duke University of Durham, NC	JP	URATE OXIDASE	2013-118803 8/5/1999	
229.	Duke University of Durham, NC	KR	URATE OXIDASE	10-2001- 7001618 8/5/1999	841634 6/20/2008
230.	Duke University of Durham, NC	MX	URATE OXIDASE	PA/A/2001/0013 42 8/5/1999	273087 1/7/2010
231.	Duke University of Durham, NC	MX	URATE OXIDASE	PA/A/2006/0071 57 8/5/1999	293491 12/9/2011
232.	Duke University of Durham, NC	MX	URATE OXIDASE	MX/A/2011/013 253 8/5/1999	308173 3/25/2013
233.	Duke University of Durham, NC	NZ	URATE OXIDASE	509633 8/5/1999	509633 8/7/2003
234.	Duke University of Durham, NC	PL	URATE OXIDASE	P-346222 8/5/1999	207369 6/28/2010
235.	Duke University of Durham, NC	RU	URATE OXIDASE	2001103131 8/5/1999	2290439 12/27/2006
236.	Duke University of Durham, NC	SG	URATE OXIDASE	200100782-2 8/5/1999	78987 11/28/2003
237.	Duke University of Durham, NC	ZA	URATE OXIDASE	2001/0974 8/5/1999	2001/0974 6/26/2002
238.	Duke University of Durham, NC	CZ	URATE OXIDASE	PV2001-466 8/5/1999	304223 4/12/2013

239.	Crealta Pharmaceuticals LLC	AU	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2006235495 4/11/2006	2006235495 7/26/2012
240.	Crealta Pharmaceuticals LLC	BR	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	PI0612941-2 4/11/2006	
241.	Crealta Pharmaceuticals LLC	CA	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2604399 4/11/2006	
242.	Crealta Pharmaceuticals LLC	CN	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	200680021018.3 4/11/2006	ZL2006800 3/27/2013

243.	Crealta Pharmaceuticals LLC	CZ	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2007-695 4/11/2006	
244.	Crealta Pharmaceuticals LLC	EP	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	06749889.9 4/11/2006	1871874 4/8/2015
245.	Crealta Pharmaceuticals LLC	EP1	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	15156612.2 4/11/2006	
246.	Crealta Pharmaceuticals LLC	FR	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	06749889.9 4/11/2006	1871874 4/8/2015
247.	Crealta Pharmaceuticals LLC	DE	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	06749889.9 4/11/2006	1871874 4/8/2015
248.	Crealta Pharmaceuticals LLC	HK	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	08106827.8 4/11/2006	
249.	Crealta Pharmaceuticals LLC	HU	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	P0700730 4/11/2006	229068 7/9/2013
250.	Crealta Pharmaceuticals LLC	IN	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	4249/KOLNP/2 007 4/11/2006	264623 1/12/2015
251.	Crealta Pharmaceuticals LLC	IE	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	06749889.9 4/11/2006	1871874 4/8/2015
252.	Crealta Pharmaceuticals LLC	IL	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	186510 4/11/2006	186510 6/25/2013
253.	Crealta Pharmaceuticals LLC	IT	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	06749889.9 4/11/2006	1871874 4/8/2015
254.	Crealta Pharmaceuticals LLC	JP	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2008-505664 4/11/2006	
255.	Crealta Pharmaceuticals LLC	JP1	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2013-009968 4/11/2006	
256.	Crealta Pharmaceuticals LLC	JP2	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2015-001805 4/11/2006	
257.	Crealta Pharmaceuticals LLC	KR	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	10-2007- 7026113 4/11/2006	
258.	Crealta Pharmaceuticals LLC	MX	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	MX/A/2007/025 487 4/11/2006	294460 1/9/2012
259.	Crealta Pharmaceuticals LLC	NZ	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	562292 4/11/2006	562292 3/11/2010
260.	Crealta Pharmaceuticals LLC	WO	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	PCT/US2006- 013660 4/11/2006	
261.	Crealta Pharmaceuticals LLC	PL	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	P-387691 4/11/2006	215285 5/22/2013
262.	Crealta Pharmaceuticals LLC	RU	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2007141625 4/11/2006	2451074 5/20/2012
263.	Crealta Pharmaceuticals LLC	RU1	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2012106116 4/11/2006	
264.	Crealta Pharmaceuticals LLC	RU2	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2012106150 4/11/2006	

265.	Crealta Pharmaceuticals LLC	RU3	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2012106148 4/11/2006	
266.	Crealta Pharmaceuticals LLC	SG	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	200716741-4 4/11/2006	
267.	Crealta Pharmaceuticals LLC	SG1	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	201002407-3 4/11/2006	161247 3/6/2014
268.	Crealta Pharmaceuticals LLC	ZA	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2007/08650 4/11/2006	2007/08650 7/29/2009
269.	Crealta Pharmaceuticals LLC	ES	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	06749889.9 4/11/2006	ES2538357 4/8/2015
270.	Crealta Pharmaceuticals LLC	CH	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	06749889.9 4/11/2006	1871874 4/8/2015
271.	Crealta Pharmaceuticals LLC	TW	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	095112937 4/11/2006	I366467 6/21/2012
272.	Crealta Pharmaceuticals LLC	TR	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	06749889.9 4/11/2006	1871874 4/8/2015
273.	Crealta Pharmaceuticals LLC	GB	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	06749889.9 4/11/2006	1871874 4/8/2015
274.	Crealta Pharmaceuticals LLC	US	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	60670573 4/11/2005	
275.	Crealta Pharmaceuticals LLC	US	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	13972167 8/21/2013	9017980 4/28/2015
276.	Crealta Pharmaceuticals LLC	US	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	14671246 3/27/2015	
277.	Crealta Pharmaceuticals LLC	US	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	13461170 5/1/2012	8541205 9/24/2013
278.	Crealta Pharmaceuticals LLC	US	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	11918297 4/11/2006	8188224 5/29/2012
279.	Crealta Pharmaceuticals LLC	AU	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2006235437 4/11/2006	2006235437 3/8/2012
280.	Crealta Pharmaceuticals LLC	AU1	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2011257764 4/11/2006	2011257764 7/19/2012
281.	Crealta Pharmaceuticals LLC	BR	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	PI0612942-0 4/11/2006	
282.	Crealta Pharmaceuticals LLC	CA	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2604545 4/11/2006	
283.	Crealta Pharmaceuticals LLC	CN	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	200680020689.8 4/11/2006	ZL2006800206 89.8 9/5/2012
284.	Crealta Pharmaceuticals LLC	CN1	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	201210246326.3 4/11/2006	
285.	Crealta Pharmaceuticals LLC	CZ	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2007-700 4/11/2006	
286.	Crealta Pharmaceuticals LLC	EP	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	06740863.3 4/11/2006	

287.	Crealta Pharmaceuticals LLC	EP1	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	14192835.8 4/11/2006	
288.	Crealta Pharmaceuticals LLC	HK	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	08106828.7 4/11/2006	
289.	Crealta Pharmaceuticals LLC	HU	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	P0700729 4/11/2006	229626 2/17/2014
290.	Crealta Pharmaceuticals LLC	IN	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	3808/KOLNP/2 007 4/11/2006	
291.	Crealta Pharmaceuticals LLC	IN1	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	4/11/2006	
292.	Crealta Pharmaceuticals LLC	IL	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	186511 4/11/2006	186511 4/1/2013
293.	Crealta Pharmaceuticals LLC	IL1	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	208643 4/11/2006	208643 12/1/2012
294.	Crealta Pharmaceuticals LLC	IL2	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	223476 4/11/2006	
295.	Crealta Pharmaceuticals LLC	IL3	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	223477 4/11/2006	
296.	Crealta Pharmaceuticals LLC	JP	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2008-505656 4/11/2006	
297.	Crealta Pharmaceuticals LLC	JP1	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2013-009960 4/11/2006	
298.	Crealta Pharmaceuticals LLC	JP2	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2015-001757 4/11/2006	
299.	Crealta Pharmaceuticals LLC	KR	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	10-2007- 7026114 4/11/2006	10-1304289 8/30/2013
300.	Crealta Pharmaceuticals LLC	MX	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	MX/N2007/012 5 4/11/2006	293490 12/9/2011
301.	Crealta Pharmaceuticals LLC	MX1	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	MX/N2011/009 9 4/11/2006	
302.	Crealta Pharmaceuticals LLC	MX2	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	MX/N2011/013 2 4/11/2006	297727 4/2/2012
303.	Crealta Pharmaceuticals LLC	NZ	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	562291 4/11/2006	562291 6/10/2010
304.	Crealta Pharmaceuticals LLC	WO	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	PCT/US2006/01 3502 4/11/2006	
305.	Crealta Pharmaceuticals LLC	PL	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	P-384263 4/11/2006	215157 4/8/2013
306.	Crealta Pharmaceuticals LLC	RU	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2007141683 4/11/2006	2435847 12/10/2011
307.	Crealta Pharmaceuticals LLC	SG	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	200716674-7 4/11/2006	

308.	Crealta Pharmaceuticals LLC	SG1	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	201002408-1 4/11/2006	161248 5/26/2014
309.	Crealta Pharmaceuticals LLC	SG2	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2014009484 4/11/2006	
310.	Crealta Pharmaceuticals LLC	ZA	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	2007/08651 4/11/2006	2007/08651 3/31/2010
311.	Crealta Pharmaceuticals LLC	TW	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	095112941 4/11/2006	
312.	Crealta Pharmaceuticals LLC	US	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	60670541 4/11/2005	
313.	Crealta Pharmaceuticals LLC	US	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	13107498 5/13/2011	8034594 10/11/2011
314.	Crealta Pharmaceuticals LLC	US	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	13226891 9/7/2011	8178334 5/15/2012
315.	Crealta Pharmaceuticals LLC	US	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	131452151 4/20/2012	8293228 10/23/2012
316.	Crealta Pharmaceuticals LLC	US	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	131623512 9/20/2012	8465735 6/18/2013
317.	Crealta Pharmaceuticals LLC	US	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	12879084 9/10/2010	7964381 6/21/2011
318.	Crealta Pharmaceuticals LLC	US	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	11918296 4/11/2006	7811800 10/12/2010

319.	Crealta Pharmaceuticals LLC	AU	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	2006339865 4/12/2006	2006339865 4/26/2012
320.	Crealta Pharmaceuticals LLC	BR	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	P10612943-9 4/12/2006	
321.	Crealta Pharmaceuticals LLC	CA	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	2611249 4/12/2006	2611249 10/14/2014
322.	Crealta Pharmaceuticals LLC	CN	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	200680021020.0 4/12/2006	ZL20068002102 0.0 1/1/2014
323.	Crealta Pharmaceuticals LLC	CZ	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	2007-701 4/12/2006	
324.	Crealta Pharmaceuticals LLC	EP	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	06749952.5 4/12/2006	2013225 12/17/2014
325.	Crealta Pharmaceuticals LLC	FR	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	06749952.5 4/12/2006	2013225 12/17/2014
326.	Crealta Pharmaceuticals LLC	DE	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	06749952.5 4/12/2006	2013225 12/17/2014
327.	Crealta Pharmaceuticals LLC	HK	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	09105691.2 4/12/2006	
328.	Crealta Pharmaceuticals LLC	HU	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	P0800388 4/12/2006	

329.	Crealta Pharmaceuticals LLC	IN	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	3807/KOLNP/2007 4/12/2006	
330.	Crealta Pharmaceuticals LLC	IE	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	06749952.5 4/12/2006	2013225 12/17/2014
331.	Crealta Pharmaceuticals LLC	IL	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	186514 4/12/2006	
332.	Crealta Pharmaceuticals LLC	IT	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	06749952.5 4/12/2006	2013225 12/17/2014
333.	Crealta Pharmaceuticals LLC	JP	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	2009-505340 4/12/2006	5033177 7/6/2012
334.	Crealta Pharmaceuticals LLC	KR	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	10-2007-7025066 4/12/2006	10-1288027 7/15/2013
335.	Crealta Pharmaceuticals LLC	MX	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	MX/A/2007/012549 4/12/2006	303165 9/6/2012
336.	Crealta Pharmaceuticals LLC	NZ	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	562293 4/12/2006	562293 10/10/2011
337.	Crealta Pharmaceuticals LLC	WO	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	PCT/US2006/013751 4/12/2006	
338.	Crealta Pharmaceuticals LLC	PL	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	P-387692 4/12/2006	
339.	Crealta Pharmaceuticals LLC	RU	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	2007141623 4/12/2006	2426738 8/20/2011
340.	Crealta Pharmaceuticals LLC	SG1	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	201102592-1 4/12/2006	170860 4/28/2015
341.	Crealta Pharmaceuticals LLC	SG	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	200716759-6 4/12/2006	
342.	Crealta Pharmaceuticals LLC	ZA	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	2007/08652 4/12/2006	2007/08652 3/31/2010
343.	Crealta Pharmaceuticals LLC	ES	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	06749952.5 4/12/2006	2013225 12/17/2014
344.	Crealta Pharmaceuticals LLC	CH	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	06749952.5 4/12/2006	2013225 12/17/2014
345.	Crealta Pharmaceuticals LLC	TW	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	095112938 4/11/2006	I418564 12/11/2013
346.	Crealta Pharmaceuticals LLC	TR	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	06749952.5 4/12/2006	2013225 12/17/2014
347.	Crealta Pharmaceuticals LLC	GB	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	06749952.5 4/12/2006	2013225 12/17/2014
348.	Crealta Pharmaceuticals LLC	US	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	60670520 4/11/2005	
349.	Crealta Pharmaceuticals LLC	US	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	11918292 4/12/2006	

350.	Crealta Pharmaceuticals LLC	AU	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	2010265964 6/25/2010	2010265964 1/25/2010
351.	Crealta Pharmaceuticals LLC	BR	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	P11010069-5 6/25/2010	
352.	Crealta Pharmaceuticals LLC	CA	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	2766309 6/25/2010	
353.	Crealta Pharmaceuticals LLC	CN	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	201080028635.2 6/25/2010	
354.	Crealta Pharmaceuticals LLC	CZ	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	PV2011-827 6/25/2010	
355.	Crealta Pharmaceuticals LLC	EP	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	10792756.8 6/25/2010	
356.	Crealta Pharmaceuticals LLC	HK	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	12110520.4 6/25/2010	
357.	Crealta Pharmaceuticals LLC	HU	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	P1200205 6/25/2010	
358.	Crealta Pharmaceuticals LLC	IN	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	59/DELNP/2012 6/25/2010	
359.	Crealta Pharmaceuticals LLC	IL	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	216956 6/25/2010	

360.	Crealta Pharmaceuticals LLC	JP	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	2012-517793 6/25/2010	
361.	Crealta Pharmaceuticals LLC	JP1	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	2015-10371 6/25/2010	
362.	Crealta Pharmaceuticals LLC	KR	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	10-2011- 7031627 6/25/2010	
363.	Crealta Pharmaceuticals LLC	MX	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	MX/A/2011/013 489 6/25/2010	
364.	Crealta Pharmaceuticals LLC	NZ	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	597089 6/25/2010	597089 9/2/2014
365.	Crealta Pharmaceuticals LLC	WO	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	PCT/US2010/04 0082 6/25/2010	
366.	Crealta Pharmaceuticals LLC	PL	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	P-398781 6/25/2010	
367.	Crealta Pharmaceuticals LLC	RU	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	2012102399 6/25/2010	2535038 12/10/2014
368.	Crealta Pharmaceuticals LLC	SG	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	201109356-4 6/25/2010	
369.	Crealta Pharmaceuticals LLC	SG1	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	10201408480R 6/25/2010	

370.	Crealta Pharmaceuticals LLC	ZA	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	2011/09339 6/25/2010	
371.	Crealta Pharmaceuticals LLC	00	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	61248698 10/5/2009	
372.	Crealta Pharmaceuticals LLC	US	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	61269669 6/25/2009	
373.	Crealta Pharmaceuticals LLC	US	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	61298718 1/27/2010	
374.	Crealta Pharmaceuticals LLC	US	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF REPSONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE	13379704 6/25/2010	
375.	Crealta Pharmaceuticals LLC and Duke University	US	METHODS FOR LOWERING ELEVATED URIC ACIDE LEVELS USING INTRAVENOUS INJECTIONS OF PEG-URICASE	11539475 4/11/2006	8148123 4/3/2012
376.	Crealta Pharmaceuticals LLC and Duke University	US	METHODS FOR LOWERING ELEVATED URIC ACIDE LEVELS USING INTRAVENOUS INJECTIONS OF PEG-URICASE	11899688 9/7/2007	
377.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	AT	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	SZ41/2013 7/4/2013	
378.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	BE	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2013C/045 7/3/2013	
379.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	CY	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	CY2013028 7/4/2013	
380.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	BR	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	CI0108386-4 2/7/2001	

381.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	DE	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	122013000058.9 7/5/13	
382.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	DK	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	CA201300038 7/5/2013	
383.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	ES	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	C300096380 7/4/2013	9/26/2014
384.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	FI	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	C20130035 7/4/2013	
385.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	FR	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	13C0036 7/4/2013	5/16/2014
386.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	GB	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	SPC/GB13/039 6/27/2013	
387.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	GR	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	20130800034 7/8/2013	
388.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	HU	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	S1300029 7/4/2013	
389.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	IE	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	2013/029 7/3/2013	
390.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	IT	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	UB2013CCP001 310	10/28/2013
391.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	LU	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	92237 7/3/2013	9/3/2013
392.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	NL	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	C300601 7/8/2013	
393.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	PL	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	0239/0208064 7/5/2013	

394.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	PT	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	549 7/8/2013	4/4/2014
395.	Mountain View Pharmaceuticals, Inc. of Menlo Park, CA and Duke University of Durham, NC	SE	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	1390031-1 6/28/2013	5/26/2014
396.	Mountain View Pharmaceuticals, Inc. and Duke University of Durham, NC	CZ	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	SPC/CZ2013-280 2/7/2001	
397.	Crealta Pharmaceuticals LLC	HU	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	S1300039 8/14/2013	
398.	Wilmington	US	Fast disintegrating compositions of meloxicam		8545879 8/20/2015